Raredr

View All Case-Studies

45-year old man with polychthemia vera is not responding to first line therapy (phlebotomy, hydroxyurea) and still has an enlarged spleen, abnormal red and white blood cell counts, and elevated platelet counts.

Peer Perspectives

A 45-year old with Polycythemia Vera not Responding to Hydroxyurea
Srdan Verstovsek, MD, PhD of the MD Anderson Cancer Center in Houston, Texas discusses a middle aged man with polycythemia vera who did not respond to initial therapy (hydroxurea) with and required another treatment option.
Cardiovascular Events and Polycythemia Vera
The leading cause of death in patients with polycythemia vera is from a cardiovascular event. Srdan Verstovsek, MD, PhD of the MD Anderson Cancer Center in Houston, Texas discusses the importance of monitoring cardiovascular measures on these patients.
Five Factors Present in Polycythemia Vera Patients Refractory to Hydroxyurea
Srdan Verstovsek, MD, PhD of the MD Anderson Cancer Center inHouston, Texas describes the 5 factors that are often present in patients with polycythemia vera who are refractory to hydroxyurea.
Treating Polycythemia Vera Patients Refractory to Hydroxyurea
In a case study of a 45-year old man with polycythemia vera is refractory to hydroxyurea, Srdan Verstovsek, MD, PhD of the MD Anderson Cancer Center in Houston, Texas describes how ruxolitinib is a viable treatment option.
10 Questions to Ask Polycythemia Vera Patients
Response to therapy in patients with polycythemia vera is complicated. Srdan Verstovsek, MD, PhD of the MD Anderson Cancer Center in Houston, Texas describes a questionnaire that can be used to properly assess how well patients are responding to treatment.
Polycythemia Vera Case Study - Final Thoughts on Ruxolitinib
Srdan Verstovsek, MD, PhD of the MD Anderson Cancer Center in Houston, Texas notes that in his experience, patients with polycythemia vera who are unresponsive to hydroxyurea tend to have much improves symptoms and quality of life once they begin ruxolitinib treatment.
The Safety and Efficacy of Ruxolitinib in Polycythemia Vera
Srdan Verstovsek, MD, PhD of the MD Anderson Cancer Center in Houston, Texas describes the RESPONSE Study showing the efficacy of ruxolitinib in patients with polycythemia vera refractory to hydroxyurea.
$vacMongoViewPlus$ $vAR$